Nabriva Therapeutics plc Sustainability Profile
Nabriva Therapeutics plc, a biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for serious infections. Founded in 2006, Nabriva has made significant strides in the antibiotic sector, particularly in the treatment of acute bacterial infections. The company is renowned for its unique portfolio of products, including its lead antibiotic, which addresses the growing challenge of antibiotic resistance. Nabriva's commitment to advancing antimicrobial therapies positions it as a key player in the global healthcare landscape. With a strong presence in both Europe and the United States, Nabriva Therapeutics continues to achieve notable milestones, reinforcing its reputation for excellence in the biopharmaceutical industry.
DitchCarbon Score
How does Nabriva Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nabriva Therapeutics plc's score of 26 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nabriva Therapeutics plc's reported carbon emissions
Nabriva Therapeutics plc, headquartered in Ireland (IE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Nabriva Therapeutics may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the biopharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Nabriva to consider developing and communicating its climate strategy in the future.
How Carbon Intensive is Nabriva Therapeutics plc's Industry?
How Carbon Intensive is Nabriva Therapeutics plc's Location?
Nabriva Therapeutics plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nabriva Therapeutics plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
